keyword
https://read.qxmd.com/read/24314015/per-oral-substitution-with-300000-iu-vitamin-d-cholecalciferol-reduces-bone-turnover-markers-in-hiv-infected-patients
#21
JOURNAL ARTICLE
Rein Jan Piso, Madeleine Rothen, Jean Pierre Rothen, Matthias Stahl, Christoph Fux
BACKGROUND: Osteoporosis and bone fractures seem to be higher in HIV-infected Patients compared to the general populations. Moreover, bone turnover markers are increased in patients on antiretroviral therapy and vitamin D deficiency is prevalent in HIV-infected patients. However, the influence of per oral cholecalciferol on bone metabolism in HIV infected patients is not well understood. METHODS: We measured the bone turnover markers in 96 HIV-infected patients: Bone specific alkaline phosphatase (BSAP), Pyridinoline (PYR), Desoxypyridinoline (DPD) and 25-OH vitamin D...
December 6, 2013: BMC Infectious Diseases
https://read.qxmd.com/read/24089064/atypical-bilateral-stress-fractures-of-the-femoral-shaft-diagnosed-by-bone-scintigraphy-in-a-woman-with-osteoporosis
#22
JOURNAL ARTICLE
Nikolaos Papandrianos, Sotiria Alexiou, Xanthi Xouria, Dimitris J Apostolopoulos
Recent case series have identified the presence of atypical insufficiency fractures at the diaphyseal femur of osteoporotic patients, which are possibly related to the long-term use of biphosphonates. We present images of a 72-year-old woman with a history of colon cancer and osteoporosis referred for bone scintigraphy because of bilateral thigh pain. No trauma or intense exercise was reported. Bone scan revealed bilateral femoral shaft stress fractures, which were confirmed by plain radiographs. In oncologic patients with osteoporosis referred for bone scintigraphy, atypical stress fractures should be included in the differential diagnosis of focal findings in the diaphyseal femur...
November 2013: Clinical Nuclear Medicine
https://read.qxmd.com/read/24015015/paget-disease-of-bone-a-classic-case-report
#23
JOURNAL ARTICLE
Y Uday Shankar, Satya Ranjan Misra, Daniel Alex Vineet, Pavitra Baskaran
Paget disease of bone (PDB) is a chronic progressive disease of the bone of uncertain etiology, characterized initially by an increase in bone resorption, followed by a disorganized and excessive formation of bone, leading to pain, fractures, and deformities. It can manifest as a monostotic or polyostotic disease. The prevalence of PDB is common in the Anglo-Saxon population, but relatively rare in India. The disease is often asymptomatic and commonly seen in an aging population. The diagnosis of the disease is mostly based on radiological examination and on biochemical markers of bone turnover...
April 2013: Contemporary Clinical Dentistry
https://read.qxmd.com/read/23824297/can-long-term-bisphosphonate-use-causes-low-energy-fractures-a-case-report
#24
JOURNAL ARTICLE
T Dandinoğlu, S Akarsu, M Karadeniz, L Tekin, S Arıbal, M Z Kıralp
Bisphosphonates are inorganic pyrophosphate analog which accumulate on the bone surface, cause osteoclast apoptosis, and inhibit bone resorption. The nitrogen-containing bisphosphonates continue to be the drug of choice for the treatment of osteoporosis in both men and women. Although histomorphometric studies including bone biopsies have not shown any evidence of microcracks, recent studies have revealed that potent bisphosphonates are responsible for the oversuppression of bone turnover leading to microdamages, reduced bone strength, and increased fracture risk...
February 2014: Osteoporosis International
https://read.qxmd.com/read/23735022/bone-mineral-density-in-adult-coeliac-disease-an-updated-review
#25
REVIEW
Alfredo J Lucendo, Alvaro García-Manzanares
INTRODUCTION AND OBJECTIVES: coeliac disease (CD) affects around 1-2 % of the world population. Most patients are now diagnosed when adults, suffering the consequences of an impaired bone mineralization. This review aims to provide an updated discussion on the relationship between low bone mineral density (BMD), osteopenia and osteoporosis, and CD. METHODS: a PubMed search restricted to the last 15 years was conducted. Sources cited in the results were also reviewed to identify potential sources of information...
March 2013: Revista Española de Enfermedades Digestivas
https://read.qxmd.com/read/23697351/-osteogenesis-imperfecta-experience-of-dona-estef%C3%A3-nia-s-hospital-orthopedics-department
#26
JOURNAL ARTICLE
Carlos Escobar, Duarte Malveiro, António Salgado, Maria Inês Santos, João Lameirão Campagnolo, Manuel Cassiano Neves
INTRODUCTION/AIMS: Osteogenesis imperfecta (OI) is a genetic disorder characterized by bone fragility and osteopenia. Treatment involves a multidisciplinary approach and aims to improve the quality of life. The authors aimed to describe the characteristics of a sample of children with OI, to evaluate the treatment and clinical outcome before and after therapy. MATERIAL AND METHODS: An observational, longitudinal, retrospective and analytic study based on data obtained from the analisys of the clinical files of all patients with OI included in the pamidronate treatment protocol in Dona Estefânia's Hospital...
January 2013: Acta Médica Portuguesa
https://read.qxmd.com/read/23686748/radiographic-features-of-osteogenesis-imperfecta
#27
JOURNAL ARTICLE
Armelle Renaud, Julie Aucourt, Jacques Weill, Julien Bigot, Anne Dieux, Louise Devisme, Antoine Moraux, Nathalie Boutry
BACKGROUND: Osteogenesis imperfecta (OI), commonly called "brittle bone disease", is a genetic disorder characterised by increased bone fragility and decreased bone density due to quantitative and/or qualitative abnormalities of type I collagen. Different types of OI exist, from mild to severe; they may lead to death, multiple bone fractures, skeletal deformity and short stature. METHODS: Severe cases are usually diagnosed before birth and may incite the parents to choose therapeutic abortion, whereas milder cases are much more difficult to diagnose and may be sometimes confused with non-accidental injury (NAI) ("child abuse") in young children...
August 2013: Insights Into Imaging
https://read.qxmd.com/read/23681089/pseudoarthrosis-in-atypical-femoral-fracture-case-report
#28
JOURNAL ARTICLE
S Giannotti, V Bottai, G Dell'Osso, G De Paola, M Ghilardi, G Guido
Atypical femoral fractures can be subsequent to a long-term biphosphonates treatment; they have a high frequency of delayed healing. The authors describe a femoral pseudoarthrosis of an atypical fracture treated with intramedullary nailing in a female after prolonged alendronate therapy. Atypical femoral fractures can be subsequent to a long-term biphosphonates treatment even if, in the literature, there is no clarity on the exact pathogenetic mechanism. The Task Force of the American Society for Bone and Mineral Research described the major and minor features to define atypical fractures and recommends that all the five major features must be present while minor features are not necessary...
November 2013: Osteoporosis International
https://read.qxmd.com/read/23608208/-what-do-we-know-about-atypical-fractures-in-patients-on-biphosphonates-treatment-a-literature-review-using-a-case-series
#29
REVIEW
A Méndez-Gil, S Prat-Fabregat, A Domingo-Trepat, M Navarro-López, P Camacho-Carrasco, A Carreño-Delgado, J A Zumbado-Dijeres, R García-Elvira, M Ríos-Martín, R García-Tarriño, O Ares-Rodríguez, J R Ballesteros-Betancourt, S Suso-Vergara
AIM: Retrospective review of long term biphosphonates treated patients who sustained a subtrochanteric or diaphyseal femoral fracture with an atypical pattern. A literature review is presented as an update of the topic. MATERIAL AND METHODS: A retrospective study was conducted on 13 subtrochanteric or diaphyseal fractures in female patients treated with biphosphonates at our institution from September 2007 to March 2011. RESULTS: Four cases of subtrochanteric fractures and 13 diaphyseal fractures were detected...
March 2013: Revista Española de Cirugía Ortopédica y Traumatología
https://read.qxmd.com/read/22947548/bisphosphonate-therapy-for-painless-fracture-change-of-hsan-1-clinical-course-with-biphosphonate-and-vitamin-d-therapy
#30
JOURNAL ARTICLE
I A Marik, A Marikova, O Hudakova, M E Samuels, K S Kozlowski
Hereditary Sensory and Autonomic Neuropathies comprise a set of 5 rare neurologic conditions, little known to radiologists as the neurologic and skin abnormalities precede the radiographic changes by months or even years. We report a Caucasian patient with a clinical history of HSAN, most consistent with subtype 1, whose progressive, destructive bone changes of the foot were not only controlled but to a degree reversed by the administration of bisphosphonates (Alendronate ) and vitamin D (Colecalciferol). The authors believe that combined bisphosphonate and vitamin D therapy is the treatment of choice for progressive bony changes in HSAN1...
September 2012: Journal of Musculoskeletal & Neuronal Interactions
https://read.qxmd.com/read/22230789/treatment-of-paget-s-disease-of-bone
#31
REVIEW
Leticia Lojo Oliveira, Antonio Torrijos Eslava
Paget's disease of bone is the paradigm of bone focal distortion with accelerated bone turnover. Over the years, a number of different drugs have been used to control its activity but, since biphosphonates were introduced for the treatment of the disease, they have become the preferred treatment. This review will update the therapeutic indications, available drugs and therapeutic response monitoring.
July 2012: Reumatología Clinica
https://read.qxmd.com/read/21928064/osteopenia-in-children-with-cerebral-palsy-can-be-treated-with-oral-alendronate
#32
JOURNAL ARTICLE
Muhammet Sukru Paksu, Sebahattin Vurucu, Abdulbaki Karaoglu, Alper Ozgur Karacalioglu, Ahmet Polat, Ozgur Yesilyurt, Bulent Unay, Ridvan Akin
PURPOSE: Cerebral palsy is one of the most common reasons of osteopenia in childhood. Patients have a significantly decreased bone mineral density, and painful fractures with minor traumas are common. Biphosphonates in the treatment of childhood osteoporosis are increasingly being used. This study aimed to evaluate the efficacy of oral alendronate treatment in children with cerebral palsy. METHODS: Twenty-six children (16 boys and 10 girls) aged 3 to 17 years who had quadriplegic cerebral palsy and osteopenia were included in the study...
February 2012: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://read.qxmd.com/read/21924217/-new-data-on-biphosphonate-therapy-are-therapeutic-holidays-advisable
#33
JOURNAL ARTICLE
Enrique Casado Burgos
Bisphosphonates are potent antiresorptive agents proven to be highly effective in vertebral and non-vertebral fractures. However, the reported complications associated with long-term use have led to questions on indefinite treatment. After administration of alendronate there is a high retention of the drug due to slow skeletal release as a result of bone resorption (half-life of more than 10 years), and it seems logical to propose a cessation of treatment (drug holidays) after prolonged treatment. The largest study published to date that assesses the effects on bone mineral density (BMD) and fractures with maintained or discontinued alendronate treatment is the FLEX (Fracture Intervention Trial Long-term Extension) trial...
September 2011: Reumatología Clinica
https://read.qxmd.com/read/21705982/bone-disease-in-thalassaemia-major-recent-advances-in-pathogenesis-and-clinical-aspects
#34
REVIEW
Nicos Skordis, Meropi Toumba
Bone is a dynamic organ, constantly changing metabolically and being remodelled through the balanced activity of osteoclast and osteoblast on trabecular surfaces. Osteoporosis represents a continuum, in which multiple pathogenic mechanisms converge to cause loss of bone mass and deterioration of microarchitecture of skeletal structure. In thalassaemia major (TM), progressive 'aging' of bone starts in early childhood, through the gradual development of an imbalance between augmented osteoclastic resorption and insufficient osteoblastic bone formation...
March 2011: Pediatric Endocrinology Reviews: PER
https://read.qxmd.com/read/21678088/-biphosphonate-induced-femoral-stress-fractures-a-new-problem-and-knowledge-so-far-case-report
#35
JOURNAL ARTICLE
R Lenz, M Ellenrieder, R Skripitz, R Bader, C Pautke, W Mittelmeier, T Tischer
During the last several years the treatment of osteoporosis with bisphosphonates has become accepted as a safe and effective procedure. However, recently there have been increasing numbers of reports of rare complications in the literature. Particularly the occurrence of atypical fractures of the femur has become a focus of interest but the problem is insufficiently known and only rarely addressed in the scientific discussion. The case illustrated here and a survey of the important facts in the recent literature highlight essential aspects of long-term bisphosphonate therapy...
December 2011: Der Orthopäde
https://read.qxmd.com/read/21466060/diffuse-vertebra-within-vertebra-appearance-at-the-adult-age-due-to-biphosphonate-pamidronate-administration-during-early-adolescence
#36
JOURNAL ARTICLE
B Coulier
We report a rare case of diffuse alteration of the vertebral bony structure fortuitously found in a 20-year-old patient and essentially characterized by an impressive "vertebra-within-vertebra" appearance. This aspect was found being the result of an unusual use of intravenous perfusions of biphosphonate (Pamidronate) during early adolescence for reflex sympathetic dystrophy after tibial fracture. The clinical applications of biphosphonates are briefly reminded and the physiopathology of the induced bone changes is explained...
January 2011: JBR-BTR: Organe de la Société Royale Belge de Radiologie (SRBR)
https://read.qxmd.com/read/21397831/-bone-prevention-in-prostate-cancer
#37
JOURNAL ARTICLE
T Bessede, N Houede, T Lebret
The bone loss and the fracture risk are enhanced in patients with hormonal deprivation for prostate cancer. The demineralisation can be quantified by BMD (Bone Mineral Density) and prevented by lifestyle and diet therapeutics or new therapeutic agents. These agents may have a preventive effect on metastasis occurrence, but it has to be confirmed. An intra-venous biphosphonate or a sub-cutaneous RANK-inhibitor administration prevent from bone metastasis-related events.
March 2011: Progrès en Urologie
https://read.qxmd.com/read/21375971/-bilateral-pathological-sub-trochanteric-fracture-in-a-long-term-biphosphonate-user
#38
JOURNAL ARTICLE
P Kľoc, L Tomčovčík, J Kľoc
The number of papers reporting the occurrence of specific pathological fractures in long-term biphosphonate users has recently increased. They refer to the forms of stress fracture probably resulting from an extreme decrease in bone turnover, which may involve sub-trochanteric or isolated transverse fractures, or short transverse fractures with a unicortical beak in an area of cortical hypertrophy. At the time of prodromal signs and symptoms, cortical bone at the site of impeding fracture appears rougher on radiographs...
2011: Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca
https://read.qxmd.com/read/21270669/epidemiology-and-treatment-costs-of-bone-metastases-from-lung-cancer-a-french-prospective-observational-multicenter-study-gfpc-0601
#39
MULTICENTER STUDY
Chantal Decroisette, Isabelle Monnet, Henri Berard, Gilles Quere, Herve Le Caer, Suzanna Bota, Clarisse Audigier-Valette, Laurence Geriniere, Jean-Marc Vernejoux, Christos Chouaid et al.
INTRODUCTION: The aim of this prospective, observational, multicenter study was to examine the epidemiology and management costs of bone metastatic disease (BMD) in patients with lung cancer. METHODS: The analysis included all patients with BMD from lung cancer diagnosed between May 2006 and May 2007 in 40 centers. We analyzed their management and the direct costs of BMD from the health care provider's perspective, using a Markov model. Skeletal-related event (SRE) was defined as pathological fractures, spinal cord compression, or hypercalcemia (clinical SRE [cSRE]) for an initial analysis; a second analysis included palliative radiotherapy and surgery (therapeutic SRE [tSRE])...
March 2011: Journal of Thoracic Oncology
https://read.qxmd.com/read/21246921/the-efficiency-of-bonviva-ibadronate-in-women-with-pre-post-menopause
#40
JOURNAL ARTICLE
Valbona Duraj, Teuta Backa, Edvin Rapushi, Artur Zoto, Enver Roshi
AIM: our aim was to see the efficiency of Bonviva(Ibadronates) among in osteoporoses among women. OBJECTIVES: We chose this medicament which has the most acceptable price by all the GDP women's family and also this medicament which is at the new line of biphosphonate (Ibadronates), and has the most commodity of taken ones per monthly. For our proposal we include in our study all women age 45 -60 years old (average 52.6 +/- 41), which have a physiologic menopause...
2010: Medicinski Arhiv
keyword
keyword
65879
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.